Mass Vaccination in a Pandemic – Benefits versus Risks: Interview with Geert Vanden Bossche + Follow-up Q&A

Mirrored from Vejon Health, 6-3-2021 (42min). Geert Vanden Bossche PhD, is an internationally recognised vaccine developer having worked as the head of the Vaccine Development Office at the German Centre for Infection Research. Coordinated Global Alliance for Vaccines and Immunisation’s Ebola Vaccine Program and contributed to the implementation of an integrated vaccine work plan in collaboration with Global Health Partners (WHO, Bill & Melinda Gates Foundation, CDC, UNICEF), regulators (FDA) and vaccine manufacturers to enable timely deployment or stockpiling of Ebola vaccine candidates. Highlighting the principle of using a prophylactic vaccine in the midst of a pandemic. Likely to create more more viral variants in the process. Sharing his perspective on mass vaccination in COVID-19.

Learn more about COVID-19. https://mcmillanresearch.com/

Follow-up, 20-3-2021

Deep Dive Q&A – Mass Vaccination in a Pandemic with Geert Vanden Bossche and Dr Philip McMillan.

Our first discussion highlighted the risk of viral “immune escape” when using a prophylactic vaccine during a pandemic. This is a follow up interview to discuss some outstanding issues. Many further questions about the science around this risk have been raised and will be addressed during this presentation. Please add any questions or concerns in a comment and we will cover as many as possible during our discussion.

Vejon Health: https://www.youtube.com/channel/UCSxeKmlI8XLrI1eMaqqM-kg